Cytokines News and Research

Latest Cytokines News and Research

Techne's R&D Systems acquires Boston Biochem assets

Techne Corporation announced today that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets of Boston Biochem, Inc., a leading developer and manufacturer of innovative ubiquitin-related research products.

4 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Strong 'innate immunity' effective in chikungunya patients

Chikungunya is transmitted by mosquitoes of the genus Aedes. The disease is spreading in the world and periodically sparks new outbreaks. Africa, Asia, the Indian Ocean and even Southern Europe are now affected.

23 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Digna Biotech and Biotecnol announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I.

17 Mar 2011

New study on how epoxyeicosatrienoic acids protect kidneys

Researchers at Georgia Health Sciences University are studying whether inhibiting an enzyme that reduces levels of a protective metabolite could halt the progression of diabetic nephropathy, or kidney disease resulting from diabetes.

16 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

CWRU: Postmenopausal women need more dental checkups

Postmenopausal women have a new health message to hear. Two annual dental checkups aren't enough. Older women need more, according to research findings from the Case Western Reserve University School of Dental Medicine and the Cleveland Clinic.

11 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Novel sortase-based techniques allow modification of a large variety of different proteins

Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.

10 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

Human umbilical cord blood-derived EPCs accelerate wound healing in diabetics

Transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) has been found to "significantly accelerate" wound closure in diabetic mouse models, said a team of Korean researchers publishing in the current issue of Cell Transplantation.

23 Feb 2011

Cytokines News and Research

Latest Cytokines News and Research

Techne's R&D Systems acquires Boston Biochem assets

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

New signaling pathway discovery sheds light on chronic dermatitis

Strong 'innate immunity' effective in chikungunya patients

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

New study on how epoxyeicosatrienoic acids protect kidneys

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

CWRU: Postmenopausal women need more dental checkups

Researchers create protein molecule for new anti-inflammatory therapies

Idera reports $6.0 million net loss for fourth quarter 2010

Novel sortase-based techniques allow modification of a large variety of different proteins

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

Research sheds new light on problem of insulin resistance in type 2 diabetes

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Human umbilical cord blood-derived EPCs accelerate wound healing in diabetics

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cytokines News and Research

Latest Cytokines News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in